US4946945A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunotherapy agents for treatment of IgE mediated allergies
Assignee: Allergy Immuno Technologies Inc
•
Filing: 1987-06-23
•
Granted: 1990-08-07
•
Expires: 2007-06-23
Abstract
Abstract A protein conjugate or mixture useful in immunotherapy composed of a biological response modifier (BRM) and an allergen is disclosed. In use the protein conjugate or mixture is combined with a pharmaceutically acceptable carrier. Cytokines, bacterial, fungal and viral immunopotentiators and thymus hormones are disclosed as suitable BRM's for use in the invention.
Inventors
- 👤 Aristo Wojdani
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:54
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/35; Y; Y10; Y10S; Y10S424/00; Y10S424/805; Y10S424/81; Y10S530/00; Y10S530/862; Y10S530/868
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
20 words
A protein conjugate useful in allergy immunotherapy comprising an allergen conjugated to biological response modifiers (BRM) which are fungal immunopotentiators.
Claim 2
Dependent Claim
20 words
A protein conjugate useful in allergy immunotherapy comprising an allergen conjugated to biological response modifiers (BRM) which are fungal immunopotentiators.
Claim 3
Dependent Claim
13 words
The protein conjugate according to claim 1 wherein the BRM is candida albican.
Claim 4
Dependent Claim
17 words
The protein conjugate according to claim 1 wherein the BRM is a cell product of candida albican.
Claim 5
Dependent Claim
21 words
The protein conjugate according to claim 3, wherein the cell product is cell wall; ribosomes; cell membranes; or candida albicans polysaccharide.
Claim 6
Dependent Claim
13 words
The protein conjugate according to claim 1 wherein the BRM is C. tropicalis.
Claim 7
Dependent Claim
16 words
The protein conjugate according to claim 1 wherein the BRM is cell products of C. tropicalis.
Claim 8
Dependent Claim
22 words
A protein mixture useful in allergy immunotherapy comprising an allergen, biological response modifiers which are fungal immunopotentiators, and a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
22 words
A protein mixture useful in allergy immunotherapy comprising an allergen, biological response modifiers which are fungal immunopotentiators, and a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
13 words
The protein mixture according to claim 7 wherein the BRM is C. tropicalis.
Claim 11
Dependent Claim
16 words
The protein mixture according to claim 7 wherein the BRM is cell products of C. tropicalis.
Claim 12
Dependent Claim
13 words
The protein mixture according to claim 7 wherein the BRM is candida albican.
Claim 13
Dependent Claim
17 words
The protein mixture according to claim 7 wherein the BRM is a cell product of candida albican.
Claim 14
Dependent Claim
21 words
The protein mixture according to claim 11 wherein the cell product is cell wall; ribosomes; cell membranes; or candida albicans polysaccharide.
Claim 15
Independent Claim
19 words
A method of preparing an immunotherapy injectant comprising reaction of BRM which are fungal immunopotentiators, with an allergen extract.
Claim 16
Independent Claim
19 words
A method of preparing an immunotherapy injectant comprising reaction of BRM which are fungal immunopotentiators, with an allergen extract.
Claim 17
Independent Claim
30 words
A method of enhancing production of allergen specific IgG in mammals comprising injecting in the mammal a therapeutically effective amount of BRM which are fungal immunopotentiators coupled to an allergen.
Claim 18
Independent Claim
30 words
A method of enhancing production of allergen specific IgG in mammals comprising injecting in the mammal a therapeutically effective amount of BRM which are fungal immunopotentiators coupled to an allergen.
Claim 19
Independent Claim
30 words
A method of enhancing production of allergen specific IgG in mammals comprising injecting in the mammal a therapeutically effective amount of BRM which are fungal immunopotentiators, mixed with an allergen.
Claim 20
Independent Claim
30 words
A method of enhancing production of allergen specific IgG in mammals comprising injecting in the mammal a therapeutically effective amount of BRM which are fungal immunopotentiators, mixed with an allergen.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-08-06 | 1994-02-05 | 1994-08-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-08-06 | 1998-02-05 | 1998-08-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-08-06 | 2002-02-05 | 2002-08-07 | $7700.00 | Window Closed / Lapsed |